Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What is the success rate of clinical drug development?

<< Previous

Bullboard Posts

Next >>

Post by Chianchinon Aug 07, 2023 4:13pm

163 Views

Post# 35576549

What is the success rate of clinical drug development?

Despite this validated effort, the overall success rate of clinical drug development remains low at 10%–15%5, 6, 7. Such persistent high failure rate raises several questions: Why 90% of clinical drug development fails despite implementation of many successful strategies in the past several decades?

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?